Axiom Clinical Research of Florida - Neurology Research, Tampa, FL

Clinical Trials

Axiom Clinical Research of Florida's ongoing and successfully completed clinical trials listing.

Stephen M. Sergay, MB BCh (MD)
Susan J. Steen, M.D.
Mark C. Cascione, M.D.
Robert G. Wilson, D.O.
Sunil S. Reddy, M.D.

Neurology Trials || Internal Medicine Trials

1993 – 1995	Tampa General Hospital: Phase IV Use of Felbamate Clinical Trial
1993 – 1995	Glaxo: Phase IV Treatment of Serious or Life-Threatening Epilepsy Clinical Trial
1993 – 1998	Syntex-Synergen: Phase III Natural History Study Trial Amyotrophic Lateral Sclerosis (ALS)
1993 – 1998	Syntext-Synergen: Phase III Amyotrophic Lateral Sclerosis (ALS) Clinical Trial
1993 – 2000	Syntex-Synergen: Phase III Amyotrophic Lateral Sclerosis (ALS) Clinical Trial
1993 – 1995	Glaxo Pharmaceuticals: Phase III Migraine Attack Clinical Trial
1996 – 1997	Glaxo Pharmaceuticals: Phase III Multiple Migraine Attack Clinical Trial
1996 – 1998	Amgen-Regeneron: Phase II Amyotrohpic Lateral Sclerosis (ALS) Clinical Trial
1997 – 1999	Genentech: Phase III Acute Ischemic Stroke Clinical Trial
1998 – 1999	Marrion-Merrell-Dow: Phase II Partial Seizures Clinical Trial
1998 – 1999	Forest Laboratories: Phase III Dementia of Alzheimer's Type Clinical Trial
1998 – 1999	Sandoz Pharmaceuticals: Phase III Acute Migraine Attack Clinical Trial
1998 – 2000	Eisai America: Phase III Alzheimer's Disease Clinical Trial
1998 – 2000	Glaxo-Wellcome: Phase III Productivity Loss Due to Migraine Clinical Trial
1998 – 2000	Amgen-Regeneron: Phase II Amyotrophic Lateral Sclerosis (ALS) Clinical Trial
1998 – 2000	Scherer DDS: Phase II Control of Symptoms of Parkinson's Disease Clinical Trial
1998 – 2000	Zeneca: Phase III Acute Treatment of Multiple Migraine Headaches Clinical Trial
1998 – 2000	Athena Neurosciences: Phase III Treatment of Spasticity Associated with Chronic Stroke Clinical Trial
1998 – 2005	Indiana University: Registry of Arrhythmias in Myotonic Muscular Dystrophy Clinical Trial
1999 – 2000	Glaxo Pharmaceuticals: Phase III Acute Treatment of a Single Migraine Attack Clinical Trial
1999 – 2001	Scherer DDS/Harris Clinical Research: Phase II Control of Symptoms in Parkinson's Disease Clinical Trial
1999 – 2001	Glaxo Wellcome: Phase III Acute Treatment of Migraine Clinical Trial
1999 – 2001	Cephalon: Phase III Myotrophin Injection in Patients with Amyotrophic Lateral Sclerosis Clinical Trial
1999 – 2001	Bristol-Myers-Squibb: Phase III Patients with Acute Stroke Clinical Trial
2000 – 2001	Glaxo Pharmaceuticals: Phase III Acute Treatment of Four Migraine Attacks Clinical Trial
2000 – 2001	Boehringer Ingelheim Pharmaceuticals: Phase II-III Acute Ischemic Stroke Clinical Trial
2000 – 2002	Bayer Pharmaceuticals: Phase III Dementia of the Alzheimer's Type Clinical Trial
2000 – 2002	Scherer DDS/MDS Harris: Phase III Management of Parkinsonian Patients Being Treated with Levodopa Clinical Trial
2000 – 2002	Hoechst Marion Roussel: Phase IV Use of Sabril in Patients with Partial Seizures Clinical Trial
2000 – 2002	Athena Neurosciences: Phase III Treatment of Spasticity Associated with Chronic Stroke Clinical Trial
2000 – 2002	AstraZeneca: Phase IV Effect of Zomig and Usual Migraine Care on Work Loss Productivity and Patient Preference Clinical Trial
2000 – 2002	AstraZeneca CNS Research: Phase IV Acute Treatment of Migraine Headaches in Adolescent Subjects Clinical Trial
2001 – 2002	Athena Neurosciences: Phase III Initiation of Therapy in Patients with Partial Seizures
2001 – 2002	NeoTherapeutics: Phase III Patients with Probable Alzheimer's Disease Clinical Trial
2001 – 2003	Novartis: Phase III Adjunctive Therapy in Children and Adults with Inadequately Controlled Partial Seizures Clinical Trial
2001 – 2003	Scherer DDS: Phase III Management of Parkinsonian Patients Being Treated with Levodopa Clinical Trial
2001 – 2003	Parke-Davis Pharmaceutical Research: Phase III Pregabalin Safety and Efficacy in Patients with Partial Seizures
2001 – 2003	Proctor & Gamble: Phase III Treatment of Acute Migraine Headache With or Without Aura Clinical Trial
2001 – 2003	Neotherapeutics: Phase III Probable Alzheimer's Disease Clinical Trial
2001 – 2003	Johnson & Johnson: Phase III Treatment of Dementia Secondary to Cerebrovascular Disease Clinical Trial
2001 – 2003	Bristol-Myers-Squibb: Phase III Demential of The Alzheimer's Type Clinical Trial
2001 – 2003	Cephalon: Phase IV Partial Onset Seizures Clinical Trial
2001 – 2003	Sanwa Kagaku Kenkyusho Co. Ltd.: Phase II Diabetic Neuropathy Clinical Trial
2001 – 2003	Glaxo SmithKline: Phase III Painful Diabetic Neuropathy Clinical Trial
2001 – 2003	Johnson & Johnson Research Foundation: Phase III Treatment of Dementia Secondary to Cerebrovascular Disease Clinical Trial
2002 – 2003	Neurocrine Biosciences: Phase II Primary Insomnia Type Clinical Trial
2002 – 2004	Suntory: Phase III Acute Ischemic Stroke Clinical Trial
2002 – 2004	Johnson & Johnson: Phase II Treatment of Psychosis of Alzheimer's Disease Clinical Trial
2002 – 2004	Serono: Phase III Tolerability of Rebif Injection With and Without the Use of Rebiject Mini in Relapsing Remitting MS Patients Clinical Trial
2002 – 2004	Biogen: Phase III Avonex Treatment in Patients with Relapsing Multiple Sclerosis (AIMS) Clinical Trial
2002 – 2004	Pharmacia: Phase III Early Parkinson's Disease Clinical Trial
2002 – 2004	AstraZeneca: Phase III Treatment of Adult Subjects with Migraine Clinical Trial
2003 – 2004	SeraCare Life Sciences: BioBank Repository: Collection of Blood, Plasma and Leukocytes with Matching Demographic, Clinical and Medical History
2003 -2004	Quigley Pharmaceuticals: Phase II Excessive Salivary Secretions Clinical Trial
2003 – 2004	GSK: Phase III Restless Leg Syndrome (RLS) Clinical Trial
2003 – 2004	PrecisionMed: Late Onset Alzheimer's Disease, Genomic Trial
2003 – 2005	ONO Pharmaceuticals: Phase III Acute Ischemic Stroke Clinical Trial
2003 – 2006	Berlex Laboratories: Phase III Relapsing Remitting Multiple Sclerosis Clinical Trial
2003 – 2008	Berlex Laboratories: Phase III Relapsing Remitting Multiple Sclerosis Clinical Trial
2003 – 2004	PrecisionMed: Early Onset Alzheimer's Disease, Genomic Trial
2003 – 2004	TAKEDA: Phase III Chronic Insomnia (Adult Subjects) Clinical Trial
2003 – 2004	TAKEDA: Phase III Chronic Insomnia (Elderly Subjects) Clinical Trial
2003 – 2004	Glaxo-Smith Kline: Phase III Epilepsy Clinical Trial
2004 – 2005	TAKEDA: Phase III Chronic Insomnia (Subjects) Clinical Trial
2004 – 2005	AstraZeneca: Phase III Treatment of Agitation Associated with Dementia (STAR Trial) Clinical Trial
2004 – 2005	PPD Development: Phase III Adult Primary Insomnia Patient with Sleep Maintenance Difficulties Clinical Trial
2004 – 2005	Pfizer: Phase III Postherpetic Neuralgia (PNN) Clinical Trial
2004 – 2005	Glaxo-Smith Kline: Phase III Partial Seizures Clinical Trial
2004 – 2005	Glaxo-Smith Kline: Phase III Restless Leg Syndrome Requiring Extended Treatment Coverage (RLS) Clinical Trial
2004 – 2006	Sanofi-Synthelabo Research: Phase II CHARISMA Clinical Trial
2004 – Present	Genentech, Inc: Phase II-III Primary Progressive Multiple Sclerosis Clinical Trial
2004 – 2008	Neurochem, Inc: Phase III Mild-to-Moderate Alzheimer's Disease Clinical Trial
2004 – 2008	Myriad Pharmaceuticals: Phase III Dementia of the Alzheimer's Type Clinical Trial
2004 – 2007	ONO Pharm, USA Inc: Phase II Mild-to-Moderate Alzheimer's Disease Clinical Trial
2004 - Present	Genzyme Corporation: Phase II Early, Active Relapsing-Remitting Multiple Sclerosis
2005 – 2006	Vernalis Development, Ltd.: Phase III Prevention of Menstrually-Related Migraine (MRM) Clinical Trial
2005 – Present	Boehringer Ingelheim Pharmaceuticals: Phase IV Open Label Ophthalmologic Safety Clinical Trial in Early Parkinson's Disease
2005 – 2006	Eisai/Pfizer, Inc.: Phase IV Open Label Safety and Effectiveness in Hispanic Mild to Moderate Alzheimer's Disease
2005 – 2006	Endo Pharmaceuticals: Phase IV Effectiveness and Safety for Acute Treatment of Menstrual Migraines
2005 – 2006	Hamilton Pharmaceuticals, Inc.: Phase III Randomized Controlled Comparison Study of Patients with Post-Stroke Apathy
2005 – 2007	GlaxoSmithKline: Phase III Randomized Double Blind Cohort Study on Safety and Tolerability in Patients with Restless Legs Syndrome (RLS)
2006 – 2008	GlaxoSmithKline: Phase III Open Label Study on Safety in Patients with Restless Legs Syndrome (RLS)
2006 – Present	Biogen Idec: Genomic Biomarker Response in Multiple Sclerosis Patients
2006 – 2006	Genomics Collaborative: Genomic, Serologic, Metabolic, and Proteomic Clinical Study in Multiple Sclerosis Patients
2006 – 2006	Somaxon Pharmaceuticals, Inc.: Phase III Randomized Double Blind Efficacy and Safety Study in Elderly Patients with Primary Sleep Maintenance Insomnia
2006 – 2007	XenoPort, Inc.: Phase II Randomized Double Blind Efficacy and Safety Study in Patients with Restless Legs Syndrome (RLS)
2006 – 2008	XenoPort, Inc.: Phase II Open Label Efficacy an Safety Study in Patients with Restless Legs Syndrome (RLS)
2006 – 2007	ENDO Pharmaceuticals: Phase III Randomized Double Blind Safety and Efficacy of Lidocaine Patch 5% in Patients with Carpal Tunnel Syndrome
2006 – Present	St. Jude Medical, Inc.: Device Trial on Atrial PFO Closure in Migraine Subjects
2006 – 2007	GlaxoSmithKline, Inc.: Study of Combination Product in Migraine Subjects with Poor Response to Eletriptan
2006 – 2007	Memory Pharmaceuticals Corporation: Multicenter Randomized Study on Safety and Efficacy in Patients with Mild to Moderate Alzheimer's
2006 – 2007	Merck & Company: Multicenter, Randomized Double Blind Study in Patients with Primary Hypercholesterolemia or Mixed Hyperlipidemia
2006 – 2008	Cognition Pharmaceuticals, Inc.: Dose Titration Study in Persons with Multiple Sclerosis with Cognitive Impairment
2006 – Present	Myriad Pharmaceuticals, Inc.: Open Label Study in Subjects with Dementia of the Alzheimer's Type
2006 – Present	Myriad Pharmaceuticals, Inc.: Phase III Multinational, Randomized, Double Blind Study on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer's Type
2006 – Present	Neurochem, Inc.: Open Label Extension in Patients with Alzheimer's Disease
2006 – Present	Novartis Pharmaceuticals Corporation: Efficacy and Safety Study of Orally Administered Medication in Patients with Relapsing-Remitting Multiple Sclerosis
2006 – Present	Novartis Pharmaceuticals Corporation: Efficacy and Safety Study of Orally Administered Medication versus Interferon B-1a in Patients with Relapsing-Remitting Multiple Sclerosis
2006 – Present	Teva Neuroscience, Inc.: Randomized Open Label Study Evaluating Scheduled Neutralizing Antibody Testing on Treatment Patterns in Multiple Sclerosis Patients
2006 – Present	XenoPort, Inc.: Open Label Extension Safety and Efficacy Study in Patients with Restless Legs Syndrome
2007 – 2008	XenoPort, Inc.: Phase II Randomized Double Blind Placebo Controlled Dose Response Efficacy and Pharmacokinetics Study in Patients with Restless Legs Syndrome (RLS)
2007 – Present	Serono, Inc.: Phase II Safety, Tolerability, and Efficacy Study of Add-on Orally Administered Medication in Multiple Sclerosis Patients with Active Disease
2007 – Present	Serono, Inc.: Phase III b Randomized, Multicenter Open Label Study in IFN-Naïve Subjects with Relapsing-Remitting Multiple Sclerosis
2007 - 2008	Bayer, Inc.: Phase III b International, Multicenter, Open Label Relapsing-Remitting Multiple Sclerosis Clinical Trial
2007 - Present	Genzyme Corporation: Phase III Relapsing-Remitting Multiple Sclerosis Clinical Trial
2007 - 2008	Novartis Pharmaceuticals Corporation.: Open Label, Randomized, Multicenter, Parallel Group Study in Patients with Probable Alzheimer's Disease
2007 - 2007	Takeda Global Research & Development Center, Inc.: Randomized, Double Blind Parallel Group Study in Adult Patients with Chronic Insomnia
2007 - Present	Genzyme Corporation: Phase III Relapsing-Remitting Multiple Sclerosis Clinical Trial in Currently Treated Patient Population
2007 – Present	Elan Pharmaceuticals: Phase III Randomized, Double Blind Efficacy & Safety Trial of Immunotherapy Agent in Alzheimer's Disease
2007 – Present	Novartis Pharmaceuticals Corporation: Phase III Randomized, Double Blind Study in Patients with Primary Progressive Multiple Sclerosis
2007 – Present	Pfizer, Inc.: Phase III Randomized, Double Blind Study in Adult Patients with Primary Insomnia
2007 – Present	Pfizer, Inc.: Phase III Randomized, Double Blind Study in Patients with Chronic Painful Diabetic Peripheral Neuropathy
2007 – Present	Sanofi-Aventis, Inc.: Phase III Randomized, Double Blind Study to Evaluate Efficacy & Safety in Patients with First Clinical Episode Suggestive of Multiple Sclerosis
2008 – Present	Eli Lilly & Co.: Phase III Randomized, Double Blind Placebo Controlled Study to Evaluate Efficacy and Safety in Patients with Central Neuropathic Pain Due to Multiple Sclerosis
2008 – Present	Toyama Pharmaceuticals, Inc.: Phase II A, Multi-Center, Randomized, Double Blind, Placebo Controlled Study to Investigate Efficacy and Safety in Patients with Mild to Moderate Alzheimer’s Disease
2008 – Present	MAP Pharmaceticals, Inc.: Phase III Randomized, Double Blind, Placebo Controlled Parallel Group Study in Adult Migraineurs for a Single Migraine Followed by Open Label Extensions to 26/52 Weeks

Updated 05/08
Updated 11/07
Updated 08/07

[ back to top ]

Internal Medicine Trials

1995 - 1996	Pfizer Phase IV Hypertensive Clinical Trial
1993 - 1996	Sankyo/Parexel Phase III Hypertensive Clinical Trial
1994 - 1996	Bristol-Myers Squibb Phase III Hypertensive Clinical Trial
1995 - 1996	Bristol-Myers Squibb Phase II Severe Hypertensive Clinical Trial
1995 - 1996	Boehringer Ingelheim Phase III Hypertensive Clinical Trial
1995 - 1996	Knoll Pharmaceutical Phase III Hypertensive Clinical Trial
1995 - 1996	Cambridge NeuroScience, Inc. Phase III Closed Head Trauma Neuroprotector Clinical Trial
1995 - 1996	Amgen, Inc. Phase IV CHF in Chronic Hemodialysis Patients
1995 - 1997	Scios Nova, Inc. Phase III Oliguric Acute Tubular Necrosis Clinical Trial
1995 - 1997	Boehringer Ingelheim Phase III ACE-Induced Cough Hypertensive Clinical Trial
1996 - 1997	Elan/Parexel Phase IV Hypertensive Clinical Trial
1996 - 1997	Merck & Co. Phase IV Factorial Hypertensive Clinical Trial
1997 - 1997	Elan/SciRex Phase IV Hypertensive Clinical Trial
1994 - 1997	SmithKline Beecham Phase II Hypertensive Clinical Trial
1995 - 1998	Parke-Davis Phase III Acute Ischemic Stroke Clinical Trial
1995 - 2001	Bristol-Myers Squibb Phase III Diabetic Nephropathy Clinical Trial
1996 - 2001	Merck & Co. Phase IV Hypertensive in LVH Clinical Trial
1997 - 1998	Searle, Inc. Phase IV Hypertensive Clinical Trial
1997 - 1999	Searle, Inc. Phase II Hypertensive Clinical Trial
1997 - 1998	Pfizer, Inc. Phase IV Isolated Systolic Hypertensive Clinical Trial
1997 - 2000	Amylin Phase III Insulin Dependent Clinical Trial
1997 - 1998	Bristol-Myers Squibb Phase II Hypertensive Clinical Trial
1997 - 1998	Bristol Myers Squibb Phase III Hypertensive Clinical Trial
1997 - 1999	Bristol Myers Squibb Phase III Hypertensive Clinical Trial
1997 - 2001	Sankyo Phase III Hypertensive Clinical Trial
1997 - 2001	Sankyo Phase III Hypertensive Clinical Trial
1997 - 1999	Whitehall-Robins Phase IV Hypertensive Clinical Trial
1997 - 1999	Bayer Phase III NIDDM Clinical Trial
1998 - 1999	Tap, Inc. Phase III Community Acquired Pneumonia Clinical Trial
1998 - 1999	Takeda America, Inc. Phase III NIDDM Clinical Trial
1998 - 2000	Novartis, Inc. Phase IV Hypercholesterolemia Clinical Trial
1998 - 2001	Elan Pharmaceuticals, Phase II Moderate to Severe Neuropathic Pain Clinical Trial
1998 - 2001	Novartis, Inc. Phase III Post Myocardial Infarction Clinical Trial
1999 - 2001	Knoll Pharmaceuticals, Phase III Anti-Arrhythmic Clinical Trial
1999 - 2001	Medco, Inc. Flo-Wire Clinical Trial
1999 - 2001	Acetelion, Inc. Phase III Congestive Heart Failure Clinical Trial
1999 - 2001	SmithKlineBeecham, Phase III Congestive Heart Failure Clinical Trial
2000 - 2001	BioPure, Inc., Phase II Blood Substitute Clinical Trial
2000 - 2001	Bristol Myers Squibb, Phase III Hypertensive with CHF Component Clinical Trial
2000 - 2001	Bristol Myers Squibb, Phase III Angioedema Clinical Trial
2000 - 2001	Merck, Inc. Phase III Hypertensive with LVH Clinical Trial
2000 - 2001	Sugen, Inc., Phase II Colorectal Cancer Clinical Trial
2000 - 2001	CATO, Inc., Phase II Non-Small Cell Lung Cancer Clinical Trial
2000 - 2001	Senju, Inc., Phase III Conjunctivitis Clinical Trial
2000 - 2001	Pfizer, Inc., Phase II Inhaled Insulin Clinical Trial
2000 - 2001	Pharmacia-Upjohn Phase III Depression Clinical Trial
2000 - 2001	Pharmacia-Upjohn Phase II Oral Diabetic Agent Clinical Trial
2000 - 2001	Novo Nordisk, Inc., Phase III Diabetic Agent Clinical Trial
2000 - 2001	Bayer, Inc., Phase IV Pediatric Quinolone Clinical Trial
2000 - 2001	AstraZeneca, Inc., Phase III Hyperlipidemia with Cardiac Component Clinical Trial
2000 - 2001	Eli Lilly, Co., Phase IV Human Growth Hormone Clinical Trial
2000 - 2001	Amgen, Inc., Phase III NESP in Hemodialysis Patients Clinical Trial Agent Clinical Trial
2000 - 2001	KOS, Inc., Phase III Hypertensive Clinical Trial
2005 - 2006	Merck, Inc., Phase III Hypercholesterolemia/Mixed Dyslipidemia Clinical Trial
2006 - 2007	Merck, Inc., Phase III Open Label Hypercholesterolemia/Mixed Dyslipidemia Clinical Trial
2007 - Present	Merck, Inc., Phase III Hypercholesterolemia/Mixed Dyslipidemia Clinical Trial
2007 - Present	Merck, Inc., Phase III Oral Diabetic Agent Clinical Trial
2007 - Present	Eli Lilly Co., Phase III Injectible Diabetic Agent Clinical Trial

[ back to top ]